LSD Therapy Shows Strong Phase 3 Results for Major Depression
Definium's single-dose LSD pill cut depression scores by 13 points vs 5 for placebo, with effects holding at 12 weeks.
Summary
Definium Therapeutics has reported promising Phase 3 trial results for DT120, a single-dose LSD-based pill for major depression. In the trial, patients taking DT120 saw their depression scores on the MADRS scale drop by 13.3 points after six weeks, compared to just 5.2 points in the placebo group. At 12 weeks, the benefit persisted — an 11-point drop versus 3.6 for placebo. This is a significant milestone for psychedelic medicine, as Phase 3 trials are the final step before potential FDA approval. Major depression is closely linked to reduced healthspan, cognitive decline, and increased mortality risk, making effective new treatments highly relevant for longevity-focused individuals.
Detailed Summary
Major depression is not just a mental health condition — it is a significant driver of accelerated aging, chronic inflammation, and reduced life expectancy. Effective treatments that go beyond conventional antidepressants are of growing interest to researchers and health-conscious individuals alike. Definium Therapeutics' Phase 3 trial results for DT120, a single oral dose of LSD, represent a meaningful step forward in psychedelic-assisted psychiatry.
The trial measured outcomes using the Montgomery-Åsberg Depression Rating Scale (MADRS), a validated clinical tool for quantifying depression severity. At six weeks post-dose, DT120 patients experienced a 13.3-point reduction in MADRS scores compared to a 5.2-point reduction in the placebo group — a difference of over 8 points, which is considered clinically meaningful. By 12 weeks, the effect modestly declined but remained robust: an 11-point drop versus 3.6 for placebo.
What makes this particularly noteworthy is the single-dose design. Unlike daily antidepressants requiring ongoing adherence, a one-time oral dose with weeks of sustained benefit suggests a fundamentally different mechanism — likely involving neuroplasticity, serotonin receptor modulation, and possibly psychological reset effects seen across psychedelic compounds.
For longevity-oriented individuals, the implications extend beyond mood. Chronic depression accelerates telomere shortening, elevates cortisol, disrupts sleep architecture, and worsens cardiovascular and metabolic health. A durable treatment that resolves depressive episodes could meaningfully improve healthspan metrics across multiple systems.
Caveats remain. The article is a brief news summary from a paywalled source, so full trial data — including safety profiles, participant demographics, dropout rates, and effect sizes in subgroups — are not yet visible. Regulatory approval is not guaranteed. Nonetheless, these Phase 3 results position LSD-based therapy as a credible near-term clinical option for treatment-resistant or standard depression.
Key Findings
- Single LSD dose (DT120) reduced depression scores by 13.3 points vs 5.2 for placebo at 6 weeks.
- Antidepressant effect largely maintained at 12 weeks with an 11-point vs 3.6-point MADRS reduction.
- Phase 3 success brings LSD-based therapy closer to potential FDA approval for major depression.
- Single-dose oral format may offer adherence advantages over daily antidepressant regimens.
- Treating depression may improve longevity biomarkers including cortisol, sleep, and cardiovascular health.
Methodology
This is a news report from STAT News, a credible specialty health and science publication. The evidence basis is a company-reported Phase 3 randomized controlled trial, the gold standard for clinical evidence. Full peer-reviewed data are not yet publicly available due to the paywalled and preliminary nature of the report.
Study Limitations
The article is a brief, paywalled news summary and does not include full trial data such as safety events, effect size statistics, or subgroup analyses. Results are company-reported and have not yet been independently peer-reviewed or published. Regulatory approval timelines and real-world efficacy may differ from controlled trial conditions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: